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SUMMARY OF PRESENTATIONS
Quality of Life Assessment
As patients with non-small cell lung cancer (NSCLC) have
improvement in survival with the current treatments, it is
becoming even more imperative to bring the tool to improve
quality of patient’s lives. Dr. Gralla discussed the assessment
of quality of life (QoL) in clinical trials and in clinical
practice.
Choosing the appropriate QoL measure is dependent on
the feasibility, reliability, and validity of the used tool. Sev-
eral tools were implemented and validated to QoL including
the Lung Cancer Symptom Scale, the EORTC, and the
FACT-L scale.1 Measuring QoL is becoming an important
end point in randomized clinical trials and more so in trials
where the smaller differences in survival are expected. Mea-
suring QoL in clinical practice and in clinical trials becomes
even valuable if it correlates with response to treatment and
more importantly to survival.
de Marinis et al.2 correlated QoL with response to
treatment in a randomized clinical trial comparing docetaxel
to pemetrexed in patients with advanced NSCLC. Although,
the standard efficacy results (survival, response rate, and
progression-free survival) of the two drugs were comparable,
the magnitude of change in Lung Cancer Symptom Scale
items correlated with patient’s response and favored one arm
over the other.
Hollen et al. examined the influence of baseline QoL
scores on patient’s survival in two large randomized trials
enrolling patients with advanced stage NSCLC. Global QoL
at baseline was correlated significantly with survival rate and
was better predictor of response than performance status or
disease stage.3 Furthermore, change in patient reported out-
come (PRO) is a better predictor of response than changes in
physiologic parameter such as forced volume capacity
(FVC). Symanowski et al.4 analyzed data from randomized
phase III trial of cisplatin with or without pemetrexed and
compared changes in PRO or FVC to treatment response.
Improvement in dyspnea alone or dyspnea and activity level
was better predictor of response than FVC. Surprisingly, PRO
results (changes in dyspnea and activity level) were as sen-
sitive predictors of survival as radiologic response to treat-
ment. These data indicate that QoL should be implemented in
the design of clinical trials to include QoL parameters as part
of eligibility criteria and an end point in the study.
Despite the importance of QoL assessment tools in
clinical decision making, they are rarely used in clinical
practice. Morris et al.5 found that 80% of oncologists believed
that QoL information should be collected before initiating
treatment, but less than 50% use it as a tool to predict survival
or predictor of response to therapy. Barriers to implementing
QoL in clinical practice include time required to perform the
analysis and perceived lack of an appropriate QoL instru-
ment. Electronic versions of QoL assessment may provide
tools to overcome those barriers.
Bone Metastasis
Bone metastases certainly leads to significant morbidity
and decrease in QL and survival in patients with lung cancer;
30 to 40% of patients with advanced stage lung cancer
present with bone metastatic disease. In those, the median
survival is less than 5 months. Bone metastases lead to
fractures in 20 to 40% of patients and spinal cord compres-
sion in 2 to 7% of patients. Dr. Ettinger discussed the current
management of bone metastases.
Biphosphonates, such as clodronate, pamidronate,
zoledronic acid, and ibandronate, alleviate bone metastases
by inhibiting osteoclast recruitment, tumor invasion, and
secretion of growth factors and stabilize osteoblastic activity.
A novel approach to treat bone metastatic disease is the use of
the human monoclonal antibody denosumab. Denosumab
decreases bone resorption by inhibiting the receptor activator
of nuclear factor-B signaling, which mediates osteoclastic
maturation, activity, and survival. A double-blinded random-
ized phase III trial comparing denosumab with zolendronic
acid in patients with advanced tumors with bone metastases
or multiple myeloma was conducted and enrolled 1776 pa-
tients.6 Denosumab was significantly better at delaying time
to first SRE, when compared with zolendronic acid (20.6
versus 16.3 months, hazard ratio [HR]  0.84, p  0.0007).
Denosumab is noninferior to zolendronic acid in the manage-
ment of bone metastatic disease. Symptoms of bone metas-
tases have significant impact on QoL of patients, and novel
strategies are directed at disrupting the osteoclastic function
by inhibiting scr, cathepsin k, and v3 integrin.
Cancer and Chemotherapy-Induced Anemia
Fatigue remains one of the main symptoms impacting
the QoL of patients with cancer. One attributer to fatigue is
cancer- and chemotherapy-induced anemia. Dr. Crawford
discussed the controversial use of Erythropoiesis-stimulating
Mountain Blue Cancer Care Center, Wheat Ridge, Colorado.
Disclosure: The author declares no conflicts of interest.
Address for correspondence: Samir E. Witta, MD, PhD, Mountain Blue
Cancer Care Center, Wheat Ridge, CO. E-mail: samir.witta@
mountainbluecare.org
Copyright © 2010 by the International Association for the Study of Lung
Cancer.
ISSN: 1556-0864/10/0512-0433
Santa Monica Supplement Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 6, December 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS472
agents (ESAs, erythropoietin, and darbepoietin) in treatment
of anemia.
Blood transfusion provides fast but temporary solution
and could be associated with allergic reactions, infection, and
fluid overload. ESAs have been approved to reduce the
number of blood transfusions required during chemotherapy.
The initial studies showed improvement in fatigue and daily
activities in patients receiving ESA, when compared with
those who did not. In those studies, fewer venous thrombo-
embolism (VTE) events were detected in patients receiving
ESAs.7 Nevertheless, later randomized trials in patients with
head and neck cancer, and lung cancer showed increased
VTE and worsened survival in patients receiving ESAs.
Three meta-analyses of randomized trials of the use of ESAs
showed 50 to 60% increase in risk of VTE in patients
receiving ESA.8–10 Hershman et al.11 analyzed data from the
Surveillance, Epidemiology and End Results-Medicare data-
base containing records from patients aged 65 years or older
who received chemotherapy between 1991 and 2002. Among
56,210 patients treated with chemotherapy, 15,346 (27%)
received ESAs. Although the proportion of patients receiving
ESAs increased from 4.8% in 1991 to 45.9% in 2002, the rate
of blood transfusion per year remained constant at 22%.
There were significantly more VTEs in patients receiving
ESAs, when compared with those who did not (22% versus
14.3%, respectively; HR  1.93, 95% confidence interval 
1.79–2.07). The impact of ESAs on survival remains contro-
versial. Early Cochrane meta-analysis showed that patients
receiving ESAs had an apparent survival advantage over
untreated patients (HR, 0.84, 95% confidence interval, 0.69–
1.02).8 Based on the initial studies, several trials were con-
ducted and four of them (ENHANCE, BEST, EPO-CAN-20,
and Amgen 103 studies) showed high mortality rate in pa-
tients receiving ESAs, when compared with the control
group. A Cochrane meta-analysis of all such studies found
that patients not receiving ESAs had longer survival time than
those who did.9 A third meta-analysis showed increase mor-
tality in patients receiving ESAs (HR, 1.17; p  0.002).10
Nevertheless, no significant increase in risk for on-study
mortality or shorter overall survival was detected in patients
who were receiving ESA and chemotherapy (HR,1.10; p 
0.12; HR, 1.04; p  0.26; respectively). To further address
the long-term safety and efficacy of darbepoietin, a random-
ized double-blinded and placebo-controlled study was initi-
ated in patients with advanced stage NSCLC receiving che-
motherapy. Alleviation of fatigue and anemia is an important
challenge in managing patients with cancer, and further
studies are needed.
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